复合磷酸酯酶肠溶片治疗肝病患者腹胀的疗效分析

Analysis of curative effect in the treatment of abdominal distension in patients with liver diseases by using Phosphoesterases Complex Enteric Coated Tablets

目的评价复合磷酸酯酶肠溶片对乙型病毒性肝炎腹胀患者的疗效,并与复方消化酶进行比较。方法107例慢性乙型病毒性肝炎以腹胀为主要症状的患者,分为复合磷酸酯酶肠溶片14 d组(1组)25例,复合磷酸酯酶肠溶片28 d组(2组)27例;复方消化酶14 d组(3组)28例,复方消化酶28 d组(4组)27例。治疗结束后观察患者腹胀的缓解率和不良反应。采用意向性分析和符合方案分析,进行卡方检验。结果复合磷酸酯酶肠溶片14 d组、复合磷酸酯酶肠溶片28 d组、复方消化酶14 d组、复方消化酶28 d组治疗后腹胀均有所缓解,行意向性分析分别为88.0%、92.6%、89.3%、96.3%,各组比较差异均无统计学意义(P>0.05);行符合方案分析分别为88.0%、96.2%、89.3%、96.0%,各组比较差异均无统计学意义(P>0.05)。结论复合磷酸酯酶肠溶片治疗肝病患者腹胀的效果好,疗效与复方消化酶相当,且无明显的不良反应。

Objective To evaluate the effect of Phosphoesterases Complex Enteric Coated Tablets in abdominal distension patients with viral hepatitis type B,and was compared with the compound digestive enzyme. Methods 107 cases of chronic hepatitis B as the main symptoms of the patients with abdominal distention,were divided into Phosphoesterases Complex Enteric Coated Tablets for 14 days group（ group 1,25 cases）,Phosphoesterases Complex Enteric Coated Tablets for 28 days group（ group 2,27 cases）,Compound Digestive Enzymes for 14 days group（ group 3,28 cases）,Compound Digestive Enzymes for 28 days group（ group 4,27 cases）. After treatment,the remission rate and adverse reaction were observed. intent- to- treat analysis and per- protocol analysis were adopted with χ2test. Results After treatment,the abdominal distension of 4 groups was released,and the results of intent- to- treat analysis were 88. 0%,92. 6%,89. 3%,96. 3%,respectively. There had no statistical difference（ P 〉 0. 05）; The results of per- protocol analysis were 88. 0%,96. 2%,89. 3%,96. 0%,respectively,and there had no statistical difference（ P 〉 0. 05）. Conclusion The curative effect of Phosphoesterases Complex Enteric Coated Tablets in the treatment of abdominal distension in patients with liver disease was good as well as Compound Digestive Enzyme,and had no obvious adverse reaction.